Nishant Vaidy, MD
Internal Medicine · West Allis, WINPI 1841510492
Payments from drug & device makers
Across 78 payments — averaging $19.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$401
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$125
- Boehringer Ingelheim$95
- Viiv Healthcare Company$91
- AstraZeneca$89
- AbbVie$88
- plus $626 from 15 others
What the payments were for
- Food & beverage$1,513100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 32 | $401 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $125 |
| Boehringer Ingelheim | 3 | $95 |
| Viiv Healthcare Company | 5 | $91 |
| AstraZeneca | 4 | $89 |
| AbbVie | 1 | $88 |
| Pfizer | 4 | $78 |
| Amgen | 3 | $69 |
| Amarin Pharma, Inc. | 3 | $66 |
| Lilly USA, LLC | 4 | $61 |
| GSK | 3 | $61 |
| Johnson & Johnson | 2 | $48 |
| Napo Pharmaceuticals Inc | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Merck | 2 | $34 |
| Boston Scientific | 1 | $30 |
| Bausch Health US, LLC | 2 | $29 |
| Sanofi Pasteur Inc. | 1 | $24 |
| Shire North American Group Inc | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Aytu Biopharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PLENVU$125
How this compares
$1,513 in reported general payments places this provider in the 90th percentile of 1,411 internal medicine providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 57 | $66,221 |
| OzempicSemaglutide | 54 | $55,340 |
| TrulicityDulaglutide | 26 | $36,105 |
| JardianceEmpagliflozin | 20 | $25,754 |
| XareltoRivaroxaban | 28 | $20,038 |
| RybelsusSemaglutide | 15 | $19,408 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 31 | $15,011 |
| FarxigaDapagliflozin Propanediol | 15 | $8,147 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $5,903 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $3,856 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 108 | $3,133 |
| Arnuity ElliptaFluticasone Furoate | 11 | $2,951 |
| Varenicline Tartrate | 14 | $2,944 |
| Atorvastatin Calcium | 315 | $2,764 |
| Omeprazole | 116 | $1,872 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $78 | $66,22157 claims |
| Lilly USA, LLCTrulicity | $61 | $36,10526 claims |
| Boehringer IngelheimJardiance | $95 | $25,75420 claims |
| Johnson & JohnsonXarelto | $48 | $20,03828 claims |
| GSKAnoro Ellipta, Arnuity Ellipta | $61 | $17,96342 claims |
| AstraZenecaFarxiga | $89 | $8,14715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,411 internal medicine providers in Wisconsin.
Other internal medicine in West Allis
- Nicholas SiebersMadison$47.3M
- Irene MirkinMiddleton$42.9M
- John BlanchardMadison$17.2M
- Carlos SanabriaWest Bend$12.9M
- Andrew KimWauwatosa$2.3M
- Jeremiah DeptaMilwaukee$2.2M
- Gilbert JenouriMilwaukee$2.2M
- Stephen FlachMadison$1.6M
- Aliaksandr TrusauGreen Bay$1.5M
- Samuel IdarragaWauwatosa$743K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.